BioSpace News Archive

Genetown

Curis Announces Encouraging Emavusertib Data at the 2022 American Society of Clinical Oncology Annual Meeting (ASCO)

Curis, Inc. announced the presentation of encouraging clinical data from both the TakeAim Lymphoma and TakeAim Leukemia studies at the 2022 American Society of Clinical Oncology Annual Meeting currently taking place in Chicago and online until June 7, 2022.

June 4, 2022
·
13 min read
Drug Development

Puma Biotechnology Presents Final Results from the Biliary Tract Cohort of the Phase 2 SUMMIT ‘Basket’ Trial of Neratinib at the ASCO 2022 Annual Meeting

Puma Biotechnology, Inc., a biopharmaceutical company, presented final results from the Phase II SUMMIT ‘basket’ trial, assessing the efficacy of neratinib in treatment-refractory patients with metastatic biliary tract cancers with somatic HER2 mutations at the 2022 American Society of Clinical Oncology Annual Meeting.

June 4, 2022
·
7 min read
BioForest

Sub-analyses of Landmark ZUMA-7 Trial Reinforce Yescarta® CAR T-cell Therapy Superiority Over Standard of Care (SOC) as Initial Treatment for Patients With Relapsed or Refractory Large B-cell Lymphoma (LBCL)

Kite, a Gilead Company, announced findings from two pre-planned, subgroup analyses of the landmark ZUMA-7 trial of Yescarta®, which led to the U.S. Food and Drug Administration’s recent expanded approval of Yescarta as initial treatment in adults with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy.

June 4, 2022
·
20 min read
Drug Development

CALQUENCE Plus Obinutuzumab Demonstrated Sustained Survival Benefit in 1st-line Chronic Lymphocytic Leukemia with 90% of Patients Surviving Five Years in ELEVATE-TN Trial

Updated results from the ELEVATE-TN Phase III trial showed AstraZeneca’s CALQUENCE® maintained a statistically significant progression-free survival benefit versus chlorambucil plus obinutuzumab and a safety and tolerability profile consistent with the known profile for CALQUENCE at a median follow up of approximately five years in combination and as a monotherapy in chronic lymphocytic leukemia.

June 4, 2022
·
22 min read
BioForest

Trodelvy® Improved Progression-Free Survival by 34% in Heavily Pre-Treated HR+/HER2- Metastatic Breast Cancer Patients

Gilead Sciences, Inc. announced positive results from the primary analysis of the Phase 3 TROPiCS-02 study of Trodelvy® versus physicians’ choice of chemotherapy in heavily pre-treated HR+/HER2- metastatic breast cancer patients who received prior endocrine therapy, CDK4/6 inhibitors and two to four lines of chemotherapy.

June 4, 2022
·
16 min read
Drug Development

Pfizer Announces Overall Survival Results from Phase 3 PALOMA-2 Trial of IBRANCE® (palbociclib) for the First-Line Treatment of ER+, HER2- Metastatic Breast Cancer

Pfizer Inc. announced overall survival results from the Phase 3 PALOMA-2 trial, which evaluated IBRANCE® in combination with letrozole compared to placebo plus letrozole for the first-line treatment of postmenopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer.

June 4, 2022
·
14 min read